Beneficial Effects of Exercise on Chemotherapy-induced Peripheral Neuropathy and Sleep Disturbance: A Review of Literature and Proposed Mechanisms
Overview
Affiliations
The goal of this narrative review is to evaluate the literature regarding exercise training as a therapy to prevent or mitigate deleterious side effects of chemotherapy, specifically peripheral neuropathy and sleep disturbances and to make concrete recommendations for implementation for the practicing oncologist. A literature search was conducted for studies that included an exercise intervention to be implemented for patients undergoing or previously treated with chemotherapy along with an analysis of its effect on either chemotherapy-induced peripheral neuropathy (CIPN) or chemotherapy-induced sleep disturbances. Studies were subsequently analyzed and summarized in order to determine the overall promise of exercise as a therapy in this setting. Five studies met inclusion criteria to be assessed with regard to the effect of exercise on CIPN and eight were included for sleep disturbances. Exercise was found to be a significantly beneficial therapy in preventing, mitigating, or improving the symptoms of CIPN and sleep disturbances in cancer patients in the majority of studies evaluated. Exercise is an effective intervention and should be specifically prescribed concurrently with chemotherapy to maximize potential of avoiding these debilitating side effects, which significantly and negatively impact quality of life in cancer survivors.
Celik A, Usta Yesilbalkan O Asia Pac J Oncol Nurs. 2024; 11(10):100581.
PMID: 39310727 PMC: 11416514. DOI: 10.1016/j.apjon.2024.100581.
Lee K, Bulls H, Hoogland A, James B, Colon-Echevarria C, Jim H Cancers (Basel). 2024; 16(14).
PMID: 39061210 PMC: 11274737. DOI: 10.3390/cancers16142571.
Seth N, Raghuveer R, Qureshi M Cureus. 2024; 16(6):e62732.
PMID: 39036239 PMC: 11260115. DOI: 10.7759/cureus.62732.
Han J, Zhang J, Zhang L, Guo J, Peng X, Ying C Front Oncol. 2024; 14:1392844.
PMID: 38741781 PMC: 11089126. DOI: 10.3389/fonc.2024.1392844.
Austin P, Lee W, Costa D, Ritchie A, Lovell M Heliyon. 2024; 10(7):e29193.
PMID: 38623224 PMC: 11016720. DOI: 10.1016/j.heliyon.2024.e29193.